Curis, Inc. - Common Stock (NQ:CRIS)

0.7688 -0.0202 (-2.56%)

Delayed Quote Updated: 12:31 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Curis, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 12, 2022

Via Benzinga

Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

December 12, 2022

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.

Via Benzinga

Earnings Outlook For Curis ↗

November 08, 2022

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an...

Via Benzinga

Why Is Curis (CRIS) Stock Up 20% Today? ↗

August 18, 2022

Curis just received a regulatory nod for its lymphoma treatment study from the FDA. Now CRIS stock traders are buying today.

Via InvestorPlace

FDA Clears Curis' Lymphoma Study, Keeping Leukemia Trial Still Stalled ↗

August 18, 2022

Via Benzinga

Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting ↗

June 06, 2022

Via Benzinga

Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket ↗

September 26, 2022

Gainers

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 30, 2022

Via Benzinga

Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold ↗

August 30, 2022

The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.

Via Benzinga

Curis's Return On Capital Employed Insights ↗

August 24, 2022

According to Benzinga Pro data, during Q2, Curis (NASDAQ:CRIS) posted sales of $2.39 million. Earnings were up 1.05%, but Curis still reported an overall loss of $15.94 million.

Via Benzinga

After Leukemia Trial, FDA Puts Partial Hold On Curis' Lymphoma Study ↗

April 11, 2022

Via Benzinga

This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗

August 19, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

Analyzing Curis Short Interest ↗

August 18, 2022

Curis (NASDAQ:CRIS) short percent of float has fallen 4.29% since its last report. The company recently reported that it has 3.58 million shares sold short, which is...

Via Benzinga

Dow Falls 60 Points; Crude Oil Rises Sharply ↗

August 18, 2022

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 60 points on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 18, 2022

Via Benzinga

BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy ↗

August 18, 2022

Bluebird Bio (BLUE) stock is on the move Thursday following FDA approval for beta-thalassemia treatment ZYNTEGLO in adults and children.

Via InvestorPlace

U.S. Stocks Turn Higher; Nasdaq Rises 50 Points ↗

August 18, 2022

U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining 50 points on Thursday.

Via Benzinga

Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

August 18, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 18, 2022

Via Benzinga

6 Penny Stocks With 1,000% Upside Potential ↗

July 24, 2022

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 06, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

June 06, 2022

Welcome back and get ready for another week of trading as we start it with the biggest pre-market stock movers for Monday!

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 03, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 31, 2022

On Tuesday, 36 companies achieved new lows for the year.

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

May 20, 2022

Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share.

Via Benzinga

Earnings Outlook For Curis ↗

May 04, 2022

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 02, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2022 ↗

April 05, 2022

Upgrades

Via Benzinga

68 Biggest Movers From Yesterday ↗

April 05, 2022

Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.